A phase I-II, open-label, multicenter trial to determine the dosimetry and safety of 99mTc-sestamibi in pediatric subjects

Sayena Azarbar, Arash Salardini, Nagib Dahdah, Joel Lazewatsky, Richard Sparks, Michael Portman, Paul D. Crane, Meng Luen Lee, Qi Zhu

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Myocardial perfusion imaging has long been used off label by practitioners attending for children with cardiac aliments. To provide clinicians with evidence-based dosage recommendation, a phase I-II, open-label, nonrandomized, multicenter trial was therefore designed using 99m Tc-sestamibi in pediatric subjects (registered under www.clinicaltrials.gov identifier no. NCT00162045). Methods: Safety and pharmacokinetic data were collected from 78 subjects using either a 1-d imaging protocol (3.7-7.4 MBq/kg, followed by 11.1 MBq/kg) or a 2-d protocol (7.4 MBq/kg for both rest and stress). Anterior and posterior planar images were collected at 15min, 1.5h, 4h, and 8h. Blood and urine samples were collected at predetermined times. Results: Subjects included 39 children (mean age ± SD, 8.5 ± 2.04 y) and 39 adolescents (mean age ± SD, 13.6 ± 1.39 y). Mean estimated organ-absorbed doses to the upper large intestine, small intestine, gallbladder wall, and lower large intestines were 0.082, 0.043, 0.042, and 0.035 mSv/MBq, respectively. All patients tolerated the radiotracer without serious adverse effects. Significant differences were observed in the liver, upper large intestine contents, and small intestine contents between rest and stress imaging. The effective dose equivalent and effective dose averages were lower in adolescents than younger children (0.011 and 0.019 mSv/MBq, respectively; P < 0.0001). Percentage injected doses (%IDs) corrected for radioactive decay in all dosimetry-evaluable subjects at 15 min and 4 h were 1.9% and 1.2% in the myocardium. Similarly in the lungs, the %ID for all dosimetry-evaluable subjects was 4.9% at 15 min after injection. At rest, the %ID in the liver decreased from a maximum of about 26% at 15 min to less than 9% at 90 min. With stress, values decreased from 15% to 7%, respectively. Conclusion: The estimates of radiation dosimetry, pharmacokinetic parameters, and safety profile in this study population are similar to published studies based on body-mass extrapolations from studies in adults. As such, applying current 99mTc-sestamibi dosing regimens for 1- and 2-d protocols based on those extrapolations will result in the expected radiation dose in children and adolescents.

Original languageEnglish (US)
Pages (from-to)728-736
Number of pages9
JournalJournal of Nuclear Medicine
Issue number5
StatePublished - May 1 2015


  • Children
  • Myocardial nuclear imaging
  • Pharmacokinetics
  • Safety

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'A phase I-II, open-label, multicenter trial to determine the dosimetry and safety of 99mTc-sestamibi in pediatric subjects'. Together they form a unique fingerprint.

Cite this